Evidence map›Paper›PMID 37242842›Full record

ArticlePolymers2023

Unlocking the Potential Use of Reactive POSS as a Coagent for EPDM/PP-Based TPV.

Nazlı Yazıcı Çakır, Özgenur İnan, Merve Ergün, Mehmet Kodal, Güralp Özkoç

Abstract read
In one paragraph

Article in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nazlı Yazıcı ÇakırDepartment of Chemical Engineering, Kocaeli University, 41001 Kocaeli, Turkey.ORCID 0000-0003-0847-2259
Özgenur İnanPolymer Science and Technology Graduate Program, Kocaeli University, 41001 Kocaeli, Turkey.
Merve ErgünDepartment of Chemical Engineering, Kocaeli University, 41001 Kocaeli, Turkey.
Mehmet KodalDepartment of Chemical Engineering, Kocaeli University, 41001 Kocaeli, Turkey.ORCID 0000-0003-0299-5411
Güralp ÖzkoçNanotechnology Research and Application Center, Sabancı University, 34956 Istanbul, Turkey.

Funding

Scientific and Technological Research Council of Turkey 119M378
6 · The paper itself

Abstract

Thermoplastic vulcanizates (TPVs) are multifunctional materials consisting of two or more phases with solid elastomeric properties at room temperatures and fluid-like properties above their melting point. They are produced through a reactive blending process known as dynamic vulcanization. The most widely produced TPV type is ethylene propylene diene monomer/polypropylene (EPDM/PP), which is the focus of this study. The peroxides are mainly selected to be used in crosslinking of EPDM/PP-based TPV. However, they still have some disadvantages, such as the side reactions resulting in the beta chain scission of the PP phase and undesired disproportionation reactions. To eliminate these disadvantages, coagents are used. In this study, for the first time, the use of vinyl functionalized polyhedral oligomeric silsesquioxane (OV-POSS) nanoparticles was investigated as a potential coagent in EPDM/PP-based TPV production via peroxide-initiated dynamic vulcanization. The properties of the TPVs having POSS were compared with the conventional TPVs containing conventional coagents, such as triallyl cyanurate (TAC). POSS content and EPDM/PP ratio were investigated as the material parameters. Mechanical properties of EPDM/PP TPVs exhibited higher values in the presence of OV-POSS, which resulted from the active participation of OV-POSS into the three-dimensional network structure of EPDM/PP during dynamic vulcanization.

Indexed as

coagentsdynamic vulcanizationPOSSthermoplastic vulcanizates

Identifiers

PMID37242842
PMCPMC10222900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.